TOKYO, Mar 18 (Pulse News Wire) – Chordia Therapeutics Inc. (190A.T) announced the initiation of the first patient dosing in the initial expansion cohort of its ongoing US phase 1/2 clinical trial for rogocekib (CTX-712).
Following recommendations from the safety evaluation committee, the company promptly communicated the decision to commence the expanded cohort to participating sites. Subsequently, multiple candidate patients were identified, leading to the successful completion of screening procedures and the administration of the first dose. Chordia Therapeutics emphasizes continued prioritization of patient safety while advancing its development plan.
Any significant progress will be disclosed promptly moving forward. Further details about the trial can be found on clinicaltrials.gov (NCT5,732,103). Chordia Therapeutics, headquartered in Fujisawa, Kanagawa Prefecture, specializes in oncology-focused drug discovery and development.
In addition to rogocekib, the company is also developing several other pipeline drugs targeting various cancer vulnerabilities, including CTX-177, a MALT1 inhibitor; CTX-439, a CDK12 inhibitor; and a GCN2 inhibitor.
🟢 Confidence: High AI-translated content.